← Oncology Approval Tracker

FDA DECISION ·

Trodelvy

sacituzumab govitecan-hziy · Immunomedics / Gilead

Accelerated approvalNew or expanded indicationUrothelial carcinoma
Open LinkedIn brief ↓

1 min read · estimated

Sources

LATER FDA ACTION

Indication withdrawn on Nov 22, 2024

FDA Project Confirm ↗

APPROVED USE

What FDA approved

Adults with locally advanced or metastatic urothelial carcinoma previously treated with platinum chemotherapy and a PD-1 or PD-L1 inhibitor. FDA withdrew this indication on November 22, 2024.

LAMPGEN ANALYSIS

Why it matters

The accelerated authorization added a distinct urothelial use that was subsequently withdrawn.

What research teams should watch

Keep the historical urothelial action separate from breast cancer uses and record its withdrawal in comparator timelines.

PRIMARY RECORDS

Sources